17,261 trials
Tuberculosis, Pulmonary
Primary: Estimate of the 14-day Early Bactericidal Activity (EBA), Based on Colony Forming Unit Counts, of the Combination of Meropenem and Amoxicillin/Clavulanate, Without…
Pulmonary Sarcoidosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 10; 8; 7; 8 Participants
Migraine · Depression
Primary: Treatment Session Adherence Rate — 7.88; 8 Number of sessions attended
Overweight · Obesity
Primary: Change in Body Weight (%) — -6.1; -6.9; -8.5; -9.5 Percentage point of body weight — p=0.0002
Pulmonary Tuberculosis
Primary: Time to Sputum Culture Conversion on Liquid Medium — 42; 28; 56; 42 days — p=0.10
Chronic Obstructive Pulmonary Disease · Emphysema
Primary: Percent Change of Circulating Anti-GRP78 IgG Levels — -17.0; -2.6 % change
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
Primary: Maximum Tolerated Dose (MTD) of Bosutinib All Phase I Participants — 400 Milligrams
Friedreich Ataxia
Primary: Percentage of Individuals With Treatment-emergent Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 5.0. — 4 Participants
Myelodysplastic Syndromes
Primary: Hematologic Improvement of Platelets (HI-P) After 4 Months on Therapy — 71.75; 18.75 platelets (/nL)
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma
Primary: PSA Decline of >= 50% (PSA50) From Baseline — 7.7 percentage of participants
Lung Neoplasm
Primary: Changes in Mean Cortical Thickness — 4.24; 7.14 percent change in mm cortical thickne
Nasal Polyps · Asthma, Aspirin-Induced · Aspirin-exacerbated Respiratory Disease
Primary: Provocative Dose 2 (PD2) During Aspirin Challenge — 121; 142 mg
Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma
Primary: Percentage of 1 Year Overall Survival (OS) — 63.6 percentage of participants
Paroxysmal Nocturnal Haemoglobinuria (PNH)
Primary: Measurement of Ratio of LDH to the Upper Limit of Normal (ULN) — 5.6; 1.9 Ratio of LDH:ULN (250 U/L)
Diabetic Foot Ulcer
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 8; 3 Participants